Kairos Pharma, LTD. - 10-Q Filing Summary (Q3 2024)
Business Context and Reporting Period
Kairos Pharma, LTD. (KAPA) is an early-stage clinical biopharmaceutical company focused on developing immunotherapy and cell therapy treatments for oncology. The company completed its Initial Public Offering (IPO) on September 17, 2024. This report covers the three and nine months ended September 30, 2024. The company has no approved products and has not generated any revenue to date.
Key Financial Metrics
| Metric (in thousands) | Three Months Ended Sept 30, 2024 | Nine Months Ended Sept 30, 2024 | Balance Sheet (Sept 30, 2024) |
|---|---|---|---|
| Revenue | $0 | $0 | N/A |
| Net Loss | $(1,047) | $(1,623) | N/A |
| Operating Expenses | $383 | $897 | N/A |
| Cash and Cash Equivalents | N/A | N/A | $3,217 |
| Total Assets | N/A | N/A | $5,004 |
| Total Liabilities | N/A | N/A | $1,672 |
| Shareholders' Equity | N/A | N/A | $3,332 |
| Weighted Avg Shares Outstanding | 10,910,227 | 10,679,776 | 12,846,785 (Issued) |
Material Changes vs. Prior Period
- Capitalization: The company transitioned from a shareholders' deficit of $(2,078) at December 31, 2023, to positive equity of $3,332 at September 30, 2024, driven by the IPO and debt conversions.
- Liquidity: Cash balances increased from $93 (Dec 31, 2023) to $3,217 (Sept 30, 2024) following the IPO, which generated $5,524 in net proceeds.
- Debt Elimination: Convertible notes payable totaling $792 principal plus accrued interest were fully converted into common stock upon the IPO closing. Related party advances were also converted to equity.
- Expense Growth: Net loss for the nine months ended Sept 30, 2024 ($1,623) increased significantly compared to the same period in 2023 ($694). This was primarily due to $537 in financing costs related to debt conversions and increased R&D expenses ($242 vs $75) associated with the initiation of Phase 2 clinical trials.
Outlook, Risks, and Unusual Items
- Going Concern: Management expects cash on hand ($3,217) to fund operations for at least 12 months from the filing date. Continued profitability and additional capital raises are required for long-term viability.
- Unusual Items: The period included significant non-cash financing costs ($537) resulting from the conversion of accounts payable and related party debt into equity at a discount to the IPO price. Additionally, $154 of debt discount amortization was recorded.
- Subsequent Events: Post-period, the company entered into a $30,000 equity line of credit with Helena Global Investment Opportunities and settled legal fees with former counsel for $150 (reducing a $773 liability).
- Controls: Management concluded that disclosure controls and procedures were not effective as of September 30, 2024.
Investor Verification Checklist
- Cash Runway: Verify the accuracy of the 12-month liquidity projection given the high burn rate and upcoming clinical trial costs.
- Dilution Impact: Review the impact of the $30,000 equity line of credit and the issuance of warrants to underwriters on future share count.
- Clinical Progress: Confirm the status and enrollment rates of the Phase 2 ENV 105 prostate and Phase 1 ENV 105 lung clinical trials.
- Internal Controls: Assess the remediation plan for the ineffective disclosure controls and procedures identified in Item 4.
- Vendor Advances: Monitor the utilization of the $1,515 in vendor advances recorded on the balance sheet for clinical services.